X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
Other Suppliers
0
USA (Orange Book)
Europe
0
Canada
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
0
0
Details:
The proceeds will be used to fund the ongoing operations of the company, including Galafold (migalastat), a small molecule and the first and only oral therapy for adults with Fabry disease and an amenable GLA variant.
Lead Product(s): Migalastat
Therapeutic Area: Genetic Disease Product Name: Galafold
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Blackstone Life Sciences
Deal Size: $30.0 million Upfront Cash: Undisclosed
Deal Type: Financing October 02, 2023
Details:
New U.S. patent titled “Methods of Treating Fabry Patients Having Renal Impairments” is directed to a molecule comprising Galafold (migalastat) bound to an alpha-galactosidase A protein, it now includes 35 issued patents, 18 of which expire in 2038.
Lead Product(s): Migalastat
Therapeutic Area: Genetic Disease Product Name: Galafold
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 19, 2022
Details:
Amicus expects to use the net proceeds in the global commercialization of Galafold for Fabry disease through geographic and label expansion, as well as support for diagnostic initiatives and the anticipated global launch of AT-GAA.
Lead Product(s): Migalastat
Therapeutic Area: Genetic Disease Product Name: Galafold
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: ARYA Sciences
Deal Size: $600.0 million Upfront Cash: $50.0 million
Deal Type: Acquisition September 29, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
